Diagnostik und klinische Bedeutung von disseminierten Tumorzellen im Knochenmark

Literatur

• 1 Borgen E, Naume B, Nesland J M, Kvalheim G, Beiske K, Fodstad Ø. et al . Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells.  Cytotherapy. 1999;  1 377-388
• 2 Braun S, Hepp F, Kentenich C RM, Janni W, Pantel K, Riethmüller G. et al . Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.  Clin Cancer Res. 1999;  5 3999-4004
• 3 Braun S, Hepp F, Sommer H L, Pantel K. Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease.  Int J Cancer (Pred Oncol). 1999;  84 1-5
• 4 Braun S, Kentenich C RM, Janni W, Hepp F, de Waal J, Willgeroth F. et al . Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.  J Clin Oncol. 2000;  18 80-86
• 5 Braun S, Müller M, Hepp F, Schlimok G, Riethmüller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.  J Natl Cancer Inst. 1998;  90 1099-1100
• 6 Braun S, Pantel K. Immunzytochemischer Tumorzellnachweis im Knochenmark - Indikationen und klinische Relevanz. In: Onkologie: Grundlagen-Diagnostik, Therapie, Entwicklungen. Zeller WJ, zur Hausen H eds). ecomed, Landsberg/Lech 1998: 1-19
• 7 Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich C RM. et al . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer.  N Engl J Med. 2000;  342 525-533
• 8 Brugger W, Bühring H J, Grünebach F, Vogel W, Kaul S, Müller R. et al . Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells.  J Clin Oncol. 1999;  17 1535-1544
• 9 Hermanek P, Hutter R V, Sobin L H, Wittekind C. Classification of isolated tumor cells and micrometastases.  Cancer. 1999;  86 2668-2673
• 10 Pantel K, Cote R J, Fodstad Ø. Detection and clinical importance of micrometastic disease.  J Natl Cancer Inst. 1999;  91 1113-1124
• 11 Pantel K, Schlimok G, Angstwurm M, Weckermann C, Schmaus W, Gath H. et al . Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.  J Hematother. 1994;  3 165-173
• 12 Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K. et al . Monoclonal antibody therapy for resected Dukes‘ C colorectal cancer: Seven-year outcome of a multicenter randomized trial.  J Clin Oncol. 1998;  16 1788-1794
• 13 Schlimok G, Funke I, Holzmann B, Göttlinger H G, Schmidt G, Häuser H. et al . Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.  Proc Natl Acad Sci USA. 1987;  84 8672-8676

Korrespondenz